Tiziana Life Sciences, Ltd. (TLSA) Files For FDA Orphan Drug Designation In MSA

Tiziana Life Sciences filed for FDA Orphan Drug Designation for intranasal foralumab to treat Multiple System Atrophy. A Phase 2a open-label MSA study is underway assessing microglial activation, clinical outcomes, and safety.Material DetailsContext by AI AnalystThis is an early regulatory step aug…